Nestlé, Swiss food company, the largest food company in the world—yes the same Nestlé that makes the cookies—has just made a $1.4 billion deal with Valeant Pharmaceuticals Inc., a skincare product company, in order to expand its new dermatology unit.
The deal includes commercial rights to sell Restylane, Perlane, and Emerval, Dysport, and Sculptra—all fancy names for injectable facial treatments for wrinkles.
For about two decades, Peter Brabeck-Lemathe, Chairman of the brand, has aimed to transform the company into a global model for health and well-being. The question lies in whether cosmetic face treatments– that sound a lot like what Botox is– fits that mold.
Yet the cosmetic dermatology industry is booming in the U.S., and the growing company plans on taking advantage of the profits that go along with these products. According to data from GlobalData Facial Aesthetics, analysts said that in the U.S., the market for wrinkle fillers is predicted to hop from $2.5 billion to $4.7 billion in five years time.
This purchase is predicted to help expand Nestlé’s brand. Who can complain about that—who doesn’t love a company that sells delicious cookies and wrinkle removers?
Photo: David Hulme
Comment Template